FY2025 · ended Dec 31, 2025 · Revenue $568.09M, -0.9% YoY · Filed Mar 5, 2026
Bioventus Inc. (BVS) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $568.1 million and net income of $22.7 million. Free cash flow was $72.1 million. As of Sep 26, 2026 it held $34.1 million in cash and investments and $244.2 million in total debt.
Revenue (TTM)
$585.64M
+3.9% vs year-ago TTM
Net income (TTM)
$57.30M
+655.0% vs year-ago TTM
Operating cash flow (TTM)
$87.43M
+56.1% vs year-ago TTM
Free cash flow (TTM)
$84.98M
+58.9% vs year-ago TTM
EPS (TTM)
$0.81
+626.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
—
Net cash
$-210.02M
as of Sep 26, 2026
Operating margin
9.7%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- BVS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Accelerated filer, Emerging growth company
- SEC CIK
- 1665988
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $568.1M | $573.3M | $512.3M | $512.1M | $430.9M |
| Operating income | $54.0M | -$15.2M | -$81.7M | -$167.2M | $12.1M |
| Net income | $22.7M | -$36.1M | -$156.2M | -$158.7M | $19.4M |
| Diluted EPS | $0.33 | -$0.56 | -$2.49 | -$2.59 | -$0.15 |
| Operating cash flow | $74.7M | $38.8M | $15.3M | -$13.5M | $23.0M |
| Free cash flow | $72.1M | $37.8M | $8.0M | -$15.0M | $9.5M |
| Total assets | $683.6M | $728.0M | $810.9M | $1.4B | $1.2B |
| Total liabilities | $455.1M | $542.4M | $589.8M | $960.4M | $618.2M |
| Stockholders' equity | $184.1M | $147.9M | $173.6M | $325.2M | $458.9M |
| Cash and investments | $53.5M | $43.5M | $40.1M | $32.8M | $73.2M |
| Total debt | $311.3M | $356.1M | $420.6M | $436.0M | $376.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 2, 2026 | Sep 26, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2026 | Nov 2, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 27, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2026 | Jun 3, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 21, 2026 | May 21, 2026 |
All 463 Bioventus Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.